Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).

被引：0

作者：

Ciccarese, Chiara

Verzoni, Elena

Bimbatti, Davide

Buti, Sebastiano

Calabro, Fabio

Galli, Luca

Scagliarini, Sarah

Fornarini, Giuseppe

Baldessari, Cinzia

Bilancia, Domenico

Facchini, Gaetano

Cattrini, Carlo

Masini, Cristina

Giganti, Maria Olga

Scandurra, Giuseppa

Nole, Franco

Berruti, Alfredo

Milella, Michele

Antonuzzo, Lorenzo

Iacovelli, Roberto

机构：

[1] Univ Cattolica Sacro Cuore, Fdn Policlin Univ A Gemelli IRCCS, Oncol Unit, Rome, Italy

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] IOV IRCCS, Ist Oncol Veneto, Oncol Unit 1, Padua, Italy

[4] Univ Hosp Parma, Fontevivo, Italy

[5] IFO Ist Regina Elena, Rome, Italy

[6] Univ Pisana, UO Oncol Med 2 Univ Azienda Osped, Pisa, Italy

[7] Cardarelli Hosp, Dept Oncol, Naples, Italy

[8] IRCCS Osped Policlin San Martino, Genoa, Italy

[9] Azienda Osped Univ Policlin Modena, Oncol Unit, Modena, Italy

[10] Azienda Osped S Carlo, Potenza, Italy

[11] SM delle Grazie Hosp, Med Oncol Unit, Pozzuoli, Italy

[12] Azienda Osped Maggiore Carita, Novara, Italy

[13] AUSL IRCCS Reggio Emilia, Reggio Emilia, Italy

[14] Osped Cremona, Cremona, Italy

[15] Humanitas Ctr Catanese Oncol, Catania, Italy

[16] IRCCS Ist Europeo Oncol, Milan, Italy

[17] Univ Brescia, Dept Med & Surg Special Radiol Sci & Publ Hlth, Med Oncol Unit, ASST Spedali Civili, Brescia, Italy

[18] Univ Verona, Sch Med, Sect Oncol, Verona, Italy

[19] Verona Univ Hosp Trust, Verona, Italy

[20] Sodc Ematol Azienda Osped Careggi, Florence, Italy

[21] Fdn Policlin Univ A Gemelli, IRCCS, Rome, Italy

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 4_SUPPL期

关键词：

283-2494-9200; 261-492-3532-2370-7650-2700; 261-492-11294; 261-492-3532-2370; 261-492-3532-2373; 261-492-5651-9270-5652; 261-492-5651-9270-5657; 4; 3; 2; 14; 319; 3581; 137; 3585; 8; 1;

D O I：

10.1200/JCO.2024.42.4_suppl.TPS494

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：TPS494 / TPS494

页数：1

共 50 条

[21] A Phase II Study of Double Immune Checkpoint Inhibitor Blockade with Nivolumab and Ipilimumab with or without Azacitidine in Patients with Myelodysplastic Syndrome (MDS)
Morita, Kiyomi
Kantarjian, Hagop M.
Bravo, Guillermo Montalban
Sasaki, Koji
Daver, Naval
Jabbour, Elias
Alvarado, Yesid
Chien, Kelly S.
DiNardo, Courtney D.
Ravandi, Farhad
Borthakur, Gautam
Bose, Prithviraj
Pemmaraju, Naveen
Naqvi, Kiran
Cortes, Jorge E.
Kadia, Tapan M.
Konopleva, Marina
Rausch, Caitlin R.
Gasior, Yvonne
Garcia-Manero, Guillermo
BLOOD, 2020, 136
[22] A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable colorectal cancer
Koenig, Julie L.
Pappas, Leon
Yeap, Beow Y.
Clark, Jeffrey William
Klempner, Samuel J.
Ryan, David P.
Allen, Jill N.
Blaszkowsky, Lawrence Scott
Giantonio, Bruce J.
Perez, Kimberly
Schlechter, Benjamin L.
Wo, Jennifer Yon-Li
Roberts, Hannah Johnson
Meyerhardt, Jeffrey A.
Ludes, Sydney D.
Zecca, Katharine
Drapek, Lorraine C.
Mehta, Arnav
Hong, Theodore S.
Parikh, Aparna Raj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[23] A phase II study of nivolumab and ipilimumab with radiation therapy in patients with metastatic, microsatellite stable pancreatic adenocarcinoma
Koenig, Julie L.
Pappas, Leon
Yeap, Beow Y.
Clark, Jeffrey William
Weekes, Colin D.
Allen, Jill N.
Blaszkowsky, Lawrence Scott
Ryan, David P.
Cleary, James M.
Mancias, Joseph Douglas
Schlechter, Benjamin L.
Slater, Sarah Elizabeth
Wo, Jennifer Yon-Li
Roberts, Hannah Johnson
Von Fedak, Sofia
Carzo, Nicole
Drapek, Lorraine C.
Mehta, Arnav
Hong, Theodore S.
Parikh, Aparna Raj
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[24] A multicenter phase II study of nivolumab plus /- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.
Chen, James Lin
Mahoney, Michelle R.
George, Suzanne
Antonescu, Cristina R.
Liebner, David A.
Van Tine, Brian Andrew
Milhem, Mohammed M.
Tap, William D.
Streicher, Howard
Schwartz, Gary K.
D'Angelo, Sandra P.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[25] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
Jain, R. K.
Chatwal, M.
Chadha, J.
Oschmann, E.
Mizelle, S.
Poehlman, T.
Fan, W.
Kim, Y.
Dhillon, J.
Wang, X.
Zhang, J.
Guevara, J-A.
Sonpavde, G. P.
ANNALS OF ONCOLOGY, 2024, 35 : S1141 - S1141
[26] Phase II clinical and immune correlate study of adjuvant nivolumab plus ipilimumab for high-risk resected melanoma
Khushalani, Nikhil, I
Vassallo, Melinda
Goldberg, Judith D.
Eroglu, Zeynep
Kim, Younchul
Cao, Biwei
Ferguson, Robert
Monson, Kelsey R.
Kirchhoff, Tomas
Amato, Carol M.
Burke, Paulo
Strange, Ann
Monk, Emily
Gibney, Geoffrey Thomas
Kudchadkar, Ragini
Markowitz, Joseph
Brohl, Andrew S.
Pavlick, Anna
Richards, Alison
Woods, David M.
Weber, Jeffrey
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (11)
[27] Nivolumab Plus Ipilimumab in Patients With Advanced Melanoma: Updated Survival, Response, and Safety Data in a Phase I Dose-Escalation Study
Callahan, Margaret K.
Kluger, Harriet
Postow, Michael A.
Segal, Neil H.
Lesokhin, Alexander
Atkins, Michael B.
Kirkwood, John M.
Krishnan, Suba
Bhore, Rafia
Horak, Christine
Wolchok, Jedd D.
Sznol, Mario
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04) : 391 - +
[28] A phase II study to evaluate the need for > two doses of nivolumab plus ipilimumab combination (combo) immunotherapy.
Postow, Michael A.
Goldman, Debra A.
Shoushtari, Alexander Noor
Warner, Allison Betof
Callahan, Margaret K.
Momtaz, Parisa
Naito, Ellesa
Eton, Omar
Nair, Suresh
Wolchok, Jedd D.
Panageas, Katherine
Chapman, Paul B.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[29] Phase II study of nivolumab and salvage nivolumab plus ipilimumab in treatment-naive patients (pts) with advanced renal cell carcinoma (RCC) (HCRN GU16-260).
Atkins, Michael B.
Jegede, Opeyemi
Haas, Naomi B.
McDermott, David F.
Bilen, Mehmet Asim
Drake, Charles G.
Sosman, Jeffrey Alan
Alter, Robert S.
Plimack, Elizabeth R.
Rini, Brian, I
Hurwitz, Michael E.
Peace, David J.
Signoretti, Sabina
Wu, Catherine J.
Catalano, Paul J.
Hammers, Hans J.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[30] Phase I/II study of BMS-986156 with ipilimumab or nivolumab with or without stereotactic ablative radiotherapy in patients with advanced solid malignancies
Chang, Joe Y.
Xu, Xinyan
Shroff, Girish S.
Comeaux, Nathan, I
Li, Wei
Rodon Ahnert, Jordi
Karp, Daniel D.
Dumbrava, Ecaterina E.
Verma, Vivek
Chen, Aileen
Welsh, James
Hong, David S.
JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2024, 12 (10)

← 1 2 3 4 5 →